Pharmanest

10 articles about Pharmanest

• Alimentiv, AcelaBio, and PharmaNest Unite To Revolutionize Precision Medicine and AI Digital Pathology For NASH/MASH Clinical Trials.

  11/8/2023

  Alimentiv Inc., AcelaBio Inc., and PharmaNest Inc. are pleased to announce their collaborative effort aimed at revolutionizing precision medicine and artificial intelligence -enabled digital pathology solutions for metabolic dysfunction-associated steatohepatitis, previously known as nonalcoholic steatohepatitis clinical trials.

• PharmaNest to Present Eight Digital Pathology and AI Abstracts at the International Liver Congress 2022PharmaNest

  6/20/2022

  PharmaNest, an emerging leader in quantitative Digital Pathology and Artificial Intelligence, announces today that it will be present, alongside with its collaborators, eight presentations at this year's International Liver Congress (ILC) in London, June 22-25, 2022.

• PharmaNest Announces New Pre-Clinical and Clinical NASH Data to Be Presented at the EASL | Digital International Liver Congress 2020

  8/24/2020

  ​​​​​PharmaNest is an image analysis company focused in the development and validation of novel standards for the quantification of Fibrosis and associated histological features for drug discovery and development. Recently, PharmaNest announced the launch of its FibroNest cloud-based and multi-vendor platform for the automated quantification of Fibrosis for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)

• PharmaNest Launches FibroNest, the First Multivendor Image Analysis and Translational Platform for the Assessment of the Severity and Progression of Fibrosis in NASH

  9/24/2019

  FibroNest cloud-based image analysis tool provides the most advanced phenotypic image analysis and translational platform for the automated quantification of fibrosis and steatosis for NASH and for other fibrotic conditions in drug discovery and drug development projects.

• Acerus Acquires Canadian Rights to Novel Pain Relief Product for Gynecological Procedures from Pharmanest

  5/29/2018

  Acerus Pharmaceuticals Corporation today announced that it has entered into an exclusive agreement to commercialize Pharmanest AB (“Pharmanest”) Short Acting Lidocaine product (“SHACT”), a novel pain relief drug device combination in Canada.

• Karolinska Development Will Receive Shares in Pharmanest AB

  11/9/2017

  Karolinska Development AB today announces that the company will receive 140,149 shares in Pharmanest AB. Furthermore, the company will receive 11,527 shares via KCIF Co-Investment Fund.

• Recipharm Invests SEK 8 Million In Pharmanest To Support The Development Of Pharmanest’s Lead Drug Candidate SHACT

  7/9/2015

• Karolinska Development AB Implements A More Prudent And Representative Approach To Reporting The Fair Value Of Its Portfolio - Divestment Of Pharmanest

  7/9/2015

• Karolinska Development AB Divests Its Holding In Pharmanest To An Investment Consortium Comprising Östersjöstiftelsen, Recipharm Venture Fund And Praktikerinvest

  7/9/2015

• Recipharm AB And Pharmanest Form Collaboration For Commercial Manufacture And Supply Of SHACT

  7/3/2014